MYOGENE BIO LLC
SPY DYS, a CRISPR-Cas gene editing therapy delivered via AAV for Duchenne muscular dystrophy
- Sector
- Biotech
- Headquarters
- Los Angeles, CA
- Total capital
- $3.8M
- Federal grants
- $3.8M
- 7 awards · 2019–2026
- Rank in peer group#368 of 392
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 3 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy$978K
- Federal grantHealth and Human S · Phase II · Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy$1.3M
- Federal grantHealth and Human S · Phase II · Pre-clinical development of SPY-DYS45-55, a CRISPR/Cas9 platform for Duchenne muscular dystrophy$499K
- Federal grantHealth and Human S · Phase I · Comparison of single versus dual vector delivery of AAV-SPY-DYS45-55 for Duchenne muscular dystrophy$150K
- Federal grantHealth and Human S · Phase II · Pre-clinical development of SPY-DYS45-55, a CRISPR/Cas9 platform for Duchenne muscular dystrophy$494K
- Federal grantHealth and Human S · Phase I · Pre-clinical development of SPY-DYS45-55, a CRISPR/Cas9 platform for Duchenne muscular dystrophy$195K
- Federal grantHealth and Human S · Phase II · Pre-clinical development of SPY-DYS45-55, a CRISPR/Cas9 platform for Duchenne muscular dystrophy$195K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 3- PendingImmunosuppressive Agents And Viral Delivery Re-dosing Methods For Gene TherapyUSPTOApplication 17998454
- PendingImmunosuppressive Agents And Viral Delivery Re-dosing Methods For Gene TherapyUSPTOApplication PCTUS2021031994
- PendingImmunosuppressive Agents And Viral Delivery Re-dosing Methods For Gene TherapyUSPTOApplication 63023767
Related companies, and why
- Kuda Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- EXCITANT THERAPEUTICS LLCSimilar federal contract value in Biotech · null in contracts
- AURATION BIOTECH INCSimilar federal contract value in Biotech · null in contracts
- AyuVis Research LimitedSimilar federal contract value in Biotech · null in contracts
- OCMS BIO LLCSimilar federal contract value in Biotech · null in contracts
- CACHE DNA, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .